Searched for
INSULIN THERAPY INNOVATIONS
Once-a-week insulin launched in India, but doctors say it won't replace daily shots for allIndia now offers Awiqli, a new once-weekly basal insulin for diabetes patients. This drug reduces annual injections from 365 to just 52 for...- Shantha Biologics to Make Injectable Drug Cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Cipla launches inhalable insulin for diabetes careCipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...
- Novo Nordisk bets on cheaper Ozempic to dominate India’s booming weight-loss marketNovo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market....
- A cure for type-1 diabetes is within reach: Breakthrough stem cell therapies show promise in 2025Hope is on the horizon for Type-1 diabetes patients. New stem cell therapies are showing remarkable progress. These treatments aim to repla...
- Can type 1 diabetes be cured? Understanding causes, genetics, ongoing research, and myths about reversalType 1 diabetes is a chronic autoimmune condition. It affects millions in the US. The body's immune system destroys insulin-producing cells...
- No more insulin shots? This 3D-printed scientific leap could change diabetes treatment foreverA global research team, led by Wake Forest University’s Dr. Quentin Perrier, has successfully 3D-printed functioning human pancreatic cells...
- Cipla shares in focus after receiving CDSCO nod to launch inhalation insulinCipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Cipla gets CDSCO nod to launch inhalation insulinCipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Chinese scientists develop cure for diabetes, insulin patient becomes medicine-free in just 3 monthsChinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no lon...
- Biocon gets US FDA nod to launch insulin glargineThe product branded as Semglee has an identical amino acid sequence to Sanofi’s Lantus® and is approved for the same indications. This is t...
- Biocon, Mylan win US court ruling in favour of insulin GlargineUS District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...
- N Rajaram on how Sanofi plans to be in pink of health in India“PM’s Ayushman Bharat policy will give an opportunity for various players in healthcare sector to grow.”
- How the keto diet could improve efficiency of a new cancer drugIf insulin is kept down with the ketogenic diet, it dramatically improves the effectiveness of these cancer drugs.
- Merck to acquire SmartCells for USD 500 mnDrug-maker Merck & Co has announced that it will buy biotechnology company SmartCells for USD 500 million.
- 'Basalog does not come under NPPA purview, NPPA should make the correction'Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...
Load More
